TAT and epilepsy: A membrane permeable peptide comprising the HIV-1 Tat domain and a TrkB sequence, able to block PLCγ1 binding to residue 816 of TrkB, has been shown to prevent epilepsy development following intra-amygdala KA while preserving the neuroprotective effects of BDNF [17].